Eli Lilly and Company announced that the U.S. Food and Drug Administration (FDA) has approved Taltz® (ixekizumab) injection 80 mg/mL for the treatment

This content is restricted to site members. If you are an existing user, please log in. New users may register below.

New User Registration
 
 
 
 
 
 
 
 
 
* Please indicate that you agree to the Terms of Service
*Required field